When should we make the critical decision to start Cardiac Myosin therapy in NYHA Class II HCM patients? Today, Dr. Patrycja Galazka is joined by Dr. Sara Saberi, Assistant Associate Professor in Cardiovascular Medicine and co-director of the Inherited Cardiomyopathy Program at the Frankel Cardiovascular Center. Together, we dive into the intricate world of Cardiac Myosin Inhibitors, addressing this vital question.

In the ever-changing landscape of HCM management, this episode offers a beacon of clarity. Whether you're a healthcare professional dedicated to improving patient outcomes or someone personally navigating the challenges of HCM, our conversation provides essential insights. Join us for a discussion that could reshape your approach to HCM care.

In the Thick of It is brought to you by the HCM Society and is produced by Earfluence.